Medicines Co. Aktie
-
Deine Einschätzung
Was spricht für und gegen Medicines Co. in den nächsten Jahren?
Pro
Kontra
Rendite von Medicines Co. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 1,72 % | -4,34 % | 17,39 % | 13,62 % | -13,24 % | -5,71 % | -28,14 % |
| Opko Health Inc. | -1,50 % | 3,15 % | 9,17 % | 17,57 % | 20,16 % | -31,10 % | -62,18 % |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 4,40 % | 4,40 % | -1,19 % | -11,23 % | -15,31 % | -38,06 % | -36,64 % |
Kommentare
News
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Most clinical-stage biotechs are small-cap companies. That makes sense. Not only can it take years -- sometimes over a decade -- to develop novel medicines, but it is also a very risky endeavor
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
The June 10 IPO of Parabilis Medicines (NASDAQ: PBLS) closed up 58% from its $20 offer price. Two days later, Space Exploration Technologies, the largest IPO in history, finished its debut up just
Why Eli Lilly Stock Jumped to a New All-Time High Today
Shares of Eli Lilly (NYSE: LLY) climbed to a record high on Friday, following several promising developments for the medicine maker.
Image source: Getty Images.
The European Medicines Agency's




